Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q3 2016
|
TNXP |
|
Phase 3 Results |
Neurology |
Special Protocol Assessment |
|
05/11/2016
|
AAAP |
|
Phase 3 Results |
Oncology |
Orphan Drug, Priority Review |
|
11/30/2016
|
LXRX |
|
510K Submission |
Oncology |
Orphan Drug, Priority Review |
|
H2 2016
|
RDHL |
|
Phase 3 Results |
Other |
Orphan Drug |
|
Q1 2017
|
OMED |
|
Phase 2 Results |
Oncology |
Orphan Drug |
|
Q1 2017
|
PTCT |
|
Phase 3 Results |
Other |
Orphan Drug |
|
H1 2017
|
CYTX |
|
Phase 3 Results |
Autoimmune |
Orphan Drug |
|
H1 2017
|
FGEN |
|
Phase 2 Results |
Respiratory |
Orphan Drug |
|
H1 2017
|
IDRA |
|
Phase 2 Results |
Oncology |
Orphan Drug |
|
H2 2018
|
MACK |
|
Phase 2 Results |
Oncology |
Orphan Drug |
|